

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Review Proposal Project

NICE Technology Appraisal No.317; Prasugrel with percutaneous coronary intervention for treating acute coronary syndrome

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Daiichi Sankyo (prasugrel) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Blood Pressure UK • British Cardiac Patients Association • Cardiac Risk in the Young • Cardiovascular Care Partnership • Circulation Foundation • Coronary Prevention Group • HEART UK • Muslim Council of Britain • Network of Sikh Organisations • Pumping Marvellous • Somerville Foundation • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Association for Nursing in Cardiovascular Care • British Atherosclerosis Society • British Cardiovascular Intervention Society • British Cardiovascular Society • British Geriatrics Society • British Heart Foundation • British Hypertension Society • British Nuclear Cardiology Society • British Society for Haematology • British Society for Haemostasis and Thrombosis • British Society for Heart Failure • British Society of Cardiovascular 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association for Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Public Health Wales NHS Trust • Scottish Medicines Consortium <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> • Accord Healthcare (clopidogrel) • Actavis UK (aspirin) • Alliance (aspirin) • AstraZeneca (ticagrelor) • Aurobindo Pharma-Milpharm (clopidogrel) • Beacon Pharmaceuticals (clopidogrel) • The Boots Company (aspirin)

Consultees	Commentators (no right to submit or appeal)
<p>Imaging</p> <ul style="list-style-type: none"> • British Thoracic Society • Clinical Leaders of Thrombosis (CLOT) • College of Emergency Medicine • National Heart Forum • Nurses Hypertension Association • Primary Care Cardiovascular Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Craniological Science and Technology • Society for Vascular Nurses • Society for Vascular Technology • UK Clinical Pharmacy Association • UK Health Forum • Vascular Society of Great Britain and Ireland <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS Gloucestershire CCG • NHS South Reading CCG • Welsh Government 	<ul style="list-style-type: none"> • Concordia International (aspirin) • Consilient Health (clopidogrel) • Ecogen Europe (aspirin) • Intrapharm laboratories (aspirin) • Reckitt Benckiser Healthcare (aspirin) • Sandoz (clopidogrel) • Zentiva (clopidogrel) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Society for Cardiovascular Research • Cardiac and cardiology research Dept, Barts • Central Cardiac Audit Database • Cochrane Heart Group • Cochrane Hypertension Group • Cochrane Peripheral Vascular Diseases Group • Cochrane Stroke Group • CODA • European Council for Cardiovascular Research • MRC Clinical Trials Unit • National Institute for Health Research • Research Institute for the Care of Older People • Wellcome Trust

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.